CoChat
Sign Up
Cited by 14Sepsis Diagnosis and TreatmentGut microbiota and healthEscherichia coli research studies

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Erythropoietin-mediated IL-17 F attenuates sepsis-induced gut microbiota dysbiosis and barrier dysfunction

Open access
Ling, Hanzhi, Lin, Yufan, Bao, Weilei, Xu, Nannan, Chen, Liping, Zhao, Lin, Liu, Chuanlong, Shen, Yecheng, Zhang, Danlu, Gong, Yuqiang, Gao, Qiuqi, Wang, Jianguang, Jin, Shengwei·2023·Biomedicine & Pharmacotherapy
DOI 10.1016/j.biopha.2023.115072
Open this paper in CoChat — free account

Abstract

Septic gut damage is critical in the progression of sepsis and multiple organ failure, characterized by gut microbiota dysbiosis and epithelium deficiency in the gut barrier. Recent studies highlight the protective effects of Erythropoietin (EPO) on multiple organs. The present study found that EPO treatment significantly alleviated the survival rate, suppressed inflammatory responses, and ameliorated intestine damage in mice with sepsis. EPO treatment also reversed sepsis-induced gut microbiota dysbiosis. The protective role of EPO in the gut barrier and microbiota was impaired after EPOR knockout. Notably, we innovatively demonstrated that IL-17 F screened by transcriptome sequencing could ameliorate sepsis and septic gut damage including gut microbiota dysbiosis and barrier dysfunction, which was verified by IL-17 F-treated fecal microbiota transplantation (FMT) as well. Our findings highlight the protection effects of EPO-mediated IL-17 F in sepsis-induced gut damage by alleviating gut barrier dysfunction and restoring gut microbiota dysbiosis. EPO and IL-17 F may be potential therapeutic targets in septic patients.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.biopha.2023.115072

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 58

  1. Fleischmann, 2016, Assessment of global incidence and mortality of hospital-treated sepsis. current estimates and limitations, Am. J. Respir. Crit. Care Med, 193, 259, 10.1164/rccm.201504-0781OC · DOI · Paper page
  2. Singer, 2016, The Third international consensus definitions for sepsis and septic shock (Sepsis-3), JAMA, 315, 801, 10.1001/jama.2016.0287 · DOI · Paper page
  3. Leventogiannis, 2022, Toward personalized immunotherapy in sepsis: The PROVIDE randomized clinical trial, Cell Rep. Med, 3
  4. Gomez, 2022, Identifying inflammatory phenotypes to target mechanism-specific treatments in sepsis, Cell Rep. Med, 3
  5. Haseeb, 2005, Collateral damage: sepsis-induced gut injury, Crit. Care Med, 33, 2439, 10.1097/01.CCM.0000182999.95340.C3 · DOI
  6. Mittal, 2014, Redefining the gut as the motor of critical illness, Trends Mol. Med, 20, 214, 10.1016/j.molmed.2013.08.004 · DOI
  7. Deng, 2023, Gut microbe-derived milnacipran enhances tolerance to gut ischemia/reperfusion injury, Cell Rep. Med, 4
  8. Haussner, 2019, Challenge to the intestinal mucosa during sepsis, Front Immunol., 10, 891, 10.3389/fimmu.2019.00891 · DOI
  9. Subramanian, 2020, Cell death of intestinal epithelial cells in intestinal diseases, Sheng Li Xue Bao, 72
  10. Coopersmith, 2003, Sepsis from Pseudomonas aeruginosa pneumonia decreases intestinal proliferation and induces gut epithelial cell cycle arrest, Crit. Care Med, 31, 1630, 10.1097/01.CCM.0000055385.29232.11 · DOI
  11. Perrone, 2012, Mechanisms of methicillin-resistant Staphylococcus aureus pneumonia-induced intestinal epithelial apoptosis, Shock, 38, 68, 10.1097/SHK.0b013e318259abdb · DOI
  12. Haak, 2018, Therapeutic potential of the gut microbiota in the prevention and treatment of sepsis, Front Immunol., 9, 2042, 10.3389/fimmu.2018.02042 · DOI
  13. Mukhopadhyay, 2022, Preterm infants at low risk for early-onset sepsis differ in early fecal microbiome assembly, Gut Microbes, 14, 2154091, 10.1080/19490976.2022.2154091 · DOI
  14. Adelman, 2020, The gut microbiome's role in the development, maintenance, and outcomes of sepsis, Crit. Care, 24, 278, 10.1186/s13054-020-02989-1 · DOI · Paper page
  15. Deng, 2022, The role of intestinal microbiota and its metabolites in intestinal and extraintestinal organ injury induced by intestinal ischemia reperfusion injury, Int J. Biol. Sci., 18, 10.7150/ijbs.71491 · DOI
  16. Deng, 2021, The gut microbiota metabolite capsiate promotes Gpx4 expression by activating TRPV1 to inhibit intestinal ischemia reperfusion-induced ferroptosis, Gut Microbes, 13, 1, 10.1080/19490976.2021.1902719 · DOI
  17. Chancharoenthana, 2022, Critical roles of sepsis-reshaped fecal virota in attenuating sepsis severity, Front Immunol., 13, 10.3389/fimmu.2022.940935 · DOI
  18. Fisher, 2003, Erythropoietin: physiology and pharmacology update, Exp. Biol. Med., 228, 1, 10.1177/153537020322800101 · DOI
  19. Ates, 2015, The protective effects of IgM-enriched immunoglobulin and erythropoietin on the lung and small intestine tissues of rats with induced sepsis: biochemical and histopathological evaluation, Pharm. Biol., 53, 78, 10.3109/13880209.2014.910535 · DOI
  20. Stoyanoff, 2018, Erythropoietin attenuates LPS-induced microvascular damage in a murine model of septic acute kidney injury, Biomed. Pharm., 107, 10.1016/j.biopha.2018.08.087 · DOI
  21. Zhang, 2015, Protective effect of erythropoietin against myocardial injury in rats with sepsis and its underlying mechanisms, Mol. Med Rep., 11, 3317, 10.3892/mmr.2015.3155 · DOI
  22. Heitrich, 2016, Erythropoietin attenuates renal and pulmonary injury in polymicrobial induced-sepsis through EPO-R, VEGF and VEGF-R2 modulation, Biomed. Pharm., 82, 606, 10.1016/j.biopha.2016.05.045 · DOI
  23. Kao, 2011, Erythropoietin improves skeletal muscle microcirculation through the activation of eNOS in a mouse sepsis model, J. Trauma. 71(, Suppl 1, S462
  24. Gao, 2015, Systemic lipopolysaccharide administration-induced cognitive impairments are reversed by erythropoietin treatment in mice, Inflammation, 38, 1949, 10.1007/s10753-015-0175-4 · DOI
  25. Elfar, 2021, Erythropoietin promotes functional recovery in a mouse model of postoperative ileus, Neurogastroenterol. Motil., 33, 10.1111/nmo.14049 · DOI
  26. Mori, 2008, Erythropoietin and its derivative protect the intestine from severe ischemia/reperfusion injury in the rat, Surgery, 143, 556, 10.1016/j.surg.2007.12.013 · DOI
  27. Kao, 2011, Recombinant human erythropoietin improves gut barrier function in a hemorrhagic shock and resuscitation rat model, J. Trauma., 71, S456
  28. Shiou, 2011, Erythropoietin protects intestinal epithelial barrier function and lowers the incidence of experimental neonatal necrotizing enterocolitis, J. Biol. Chem., 286, 12123, 10.1074/jbc.M110.154625 · DOI
  29. Ananthan, 2022, Early erythropoietin for preventing necrotizing enterocolitis in preterm neonates - an updated meta-analysis, Eur. J. Pedia, 181, 10.1007/s00431-022-04394-y · DOI
  30. Zhu, 2022, Gut microbiota correlates with clinical responsiveness to erythropoietin in hemodialysis patients with anemia, Front Cell Infect. Microbiol, 12, 10.3389/fcimb.2022.919352 · DOI
  31. Delgado, 2016, Cell death at the intestinal epithelial front line, FEBS J., 283, 2701, 10.1111/febs.13575 · DOI
  32. Berg, 1999, Bacterial translocation from the gastrointestinal tract, Adv. Exp. Med Biol., 473, 11, 10.1007/978-1-4615-4143-1_2 · DOI
  33. Rogiers, 1997, Erythropoietin response is blunted in critically ill patients, Intensive Care Med, 23, 159, 10.1007/s001340050310 · DOI
  34. Abel, 1996, Serum erythropoietin levels in patients with sepsis and septic shock, Eur. J. Haematol., 57, 359, 10.1111/j.1600-0609.1996.tb01393.x · DOI
  35. Stoyanoff, 2014, Amelioration of lipopolysaccharide-induced acute kidney injury by erythropoietin: involvement of mitochondria-regulated apoptosis, Toxicology, 318, 13, 10.1016/j.tox.2014.01.011 · DOI
  36. Altshuler, 2014, Transmural intestinal wall permeability in severe ischemia after enteral protease inhibition, PLoS One, 9, 10.1371/journal.pone.0096655 · DOI
  37. Wells, 2017, Homeostasis of the gut barrier and potential biomarkers, Am. J. Physiol. Gastrointest. Liver Physiol., 312, 10.1152/ajpgi.00048.2015 · DOI
  38. Peterson, 2014, Intestinal epithelial cells: regulators of barrier function and immune homeostasis, Nat. Rev. Immunol., 14, 141, 10.1038/nri3608 · DOI
  39. MacRedmond, 2009, Erythropoietin inhibits respiratory epithelial cell apoptosis in a model of acute lung injury, Eur. Respir. J., 33, 1403, 10.1183/09031936.00084608 · DOI
  40. Juul, 2001, Erythropoietin acts as a trophic factor in neonatal rat intestine, Gut, 49, 182, 10.1136/gut.49.2.182 · DOI
  41. Nakamura, 2015, Erythropoietin attenuates intestinal inflammation and promotes tissue regeneration, Scand. J. Gastroenterol., 50, 1094, 10.3109/00365521.2015.1020861 · DOI
  42. Donadei, 2019, Erythropoietin inhibits SGK1-dependent TH17 induction and TH17-dependent kidney disease, JCI Insight, 5, 10.1172/jci.insight.127428 · DOI
  43. de Oliveira, 2017, Study of association between interleukin-17 and interferon-gamma and recombinant human erythropoietin dose in patients undergoing peritoneal dialysis, Cytokine, 96, 24, 10.1016/j.cyto.2017.02.019 · DOI
  44. Ge, 2020, Biology of interleukin-17 and its pathophysiological significance in sepsis, Front Immunol., 11, 1558, 10.3389/fimmu.2020.01558 · DOI
  45. Ogiku, 2012, Interleukin-17A plays a pivotal role in polymicrobial sepsis according to studies using IL-17A knockout mice, J. Surg. Res, 174, 142, 10.1016/j.jss.2010.11.901 · DOI
  46. Morrow, 2019, Ford mL. IL-17, IL-27, and IL-33: a novel axis linked to immunological dysfunction during sepsis, Front Immunol., 10, 1982, 10.3389/fimmu.2019.01982 · DOI
  47. Chang, 2007, A novel heterodimeric cytokine consisting of IL-17 and IL-17F regulates inflammatory responses, Cell Res, 17, 435, 10.1038/cr.2007.35 · DOI
  48. Starnes, 2002, Cutting edge: IL-17D, a novel member of the IL-17 family, stimulates cytokine production and inhibits hemopoiesis, J. Immunol., 169, 642, 10.4049/jimmunol.169.2.642 · DOI · Paper page
  49. Wang, 2023, Gut microbiota-derived metabolites mediate the neuroprotective effect of melatonin in cognitive impairment induced by sleep deprivation, Microbiome, 11, 17, 10.1186/s40168-022-01452-3 · DOI · Paper page
  50. Yadegar, 2023, Beneficial effects of fecal microbiota transplantation in recurrent Clostridioides difficile infection, Cell Host Microbe, 31, 695, 10.1016/j.chom.2023.03.019 · DOI
  51. Chen, 2019, Fecal microbiota transplantation in cancer management: Current status and perspectives, Int J. Cancer, 145, 10.1002/ijc.32003 · DOI
  52. Imdad, 2023, Fecal transplantation for treatment of inflammatory bowel disease, Cochrane Database Syst. Rev., 4, CD012774
  53. Niu, 2021, Crosstalk between gut microbiota and sepsis, Burns Trauma, tkab036, 10.1093/burnst/tkab036 · DOI · Paper page
  54. Li, 2015, Successful treatment of severe sepsis and diarrhea after vagotomy utilizing fecal microbiota transplantation: a case report, Crit. Care, 19, 37, 10.1186/s13054-015-0738-7 · DOI
  55. Wei, 2016, Successful treatment with fecal microbiota transplantation in patients with multiple organ dysfunction syndrome and diarrhea following severe sepsis, Crit. Care, 20, 332, 10.1186/s13054-016-1491-2 · DOI
  56. Assimakopoulos, 2021, Fecal microbiota transplantation and hydrocortisone ameliorate intestinal barrier dysfunction and improve survival in a rat model of cecal ligation and puncture-induced sepsis, Shock, 55, 10.1097/SHK.0000000000001566 · DOI
  57. Liang, 2022, Metformin attenuated sepsis-related liver injury by modulating gut microbiota, Emerg. Microbes Infect., 11, 10.1080/22221751.2022.2045876 · DOI
  58. He, 2022, Interleukin-17 weakens the NAFLD/NASH process by facilitating intestinal barrier restoration depending on the gut microbiota, mBio, 13, 10.1128/mbio.03688-21 · DOI

Cited by

Sorted by citations

Metadata

Authors
Ling, H., Lin, Y., Bao, W., Xu, N., Chen, L., Zhao, L., Liu, C., Shen, Y., Zhang, D., Gong, Y., Gao, Q., Wang, J., & Jin, S.
Affiliations
Wenzhou Medical University (CN)
Corresponding author
  • Gong, Yuqiang
  • Gao, Qiuqi
  • Wang, Jianguang
  • Jin, Shengwei
ORCID
Venue
Biomedicine & Pharmacotherapy
Publisher
Elsevier BV
Published
2023-09
Volume
165
Pages
115072
ISSN
0753-3322 (ISSN-L)
DOI
10.1016/j.biopha.2023.115072
OpenAlex
W4382361754
Cited by
14
References
2
Citations by year
2026: 7 · 2025: 6 · 2024: 1
FWCI
2.79
Type
journal article
Language
en
Open access
Licence
Locations
  • Biomedicine & Pharmacotherapy (publishedVersion, cc-by-nc-nd)
  • SSRN Electronic Journal (acceptedVersion)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • National Key Research and Development Program of China (2022YFC2504404)
  • National Natural Science Foundation of China (82270098, 82272451, U22A20273)
Topics
  • Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Life Sciences › Immunology and Microbiology › Microbiology › Escherichia coli research studies
Keywords
erythropoietin, IL-17F, sepsis, gut dysbiosis, intestinal barrier dysfunction, fecal microbiota transplantation, intestinal inflammation, therapeutic target
MeSH terms
Gastrointestinal Microbiome, Animals, Erythropoietin, Sepsis, Interleukin-17, Mice, Dysbiosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review